Altimmune (ALT) Total Current Liabilities (2010 - 2026)

Altimmune (ALT) has 17 years of Total Current Liabilities data on file, last reported at $11.3 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 15.56% year-over-year to $11.3 million in Q1 2026; TTM through Mar 2026 was $11.3 million, a 15.56% increase from a year earlier, with the FY2025 full-year figure at $15.0 million, up 43.27% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $11.3 million, down from $15.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for ALT reached as high as $19.1 million in Q1 2022 and fell as low as $8.6 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $12.9 million across 5 years, with a median of $12.1 million in 2023.
• Across the five-year window, Total Current Liabilities soared 94.67% in 2022 and sank 39.16% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $17.1 million in 2022, then decreased by 28.8% to $12.1 million in 2023, then decreased by 13.79% to $10.5 million in 2024, then soared by 43.27% to $15.0 million in 2025, then fell by 24.5% to $11.3 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $11.3 million in Q1 2026, $15.0 million in Q4 2025, and $12.6 million in Q3 2025.